Itraconazole solution: Summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons

Pharmacological Research

Volumn 46, Issue 2, 2002, Pages 195-201

  Koks, C H W ^a   Meenhorst, P L ^a   Bult, A ^b   Beijnen, J H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

HIV; Itraconazole; OPC

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ASTEMIZOLE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 3A4; ERYTHROMYCIN; FLUCONAZOLE; HYDROXYITRACONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ISONIAZID; ITRACONAZOLE; LIVER ENZYME; MEVINOLIN; MIDAZOLAM; NELFINAVIR; PHENYTOIN; PIMOZIDE; PROTEINASE INHIBITOR; QUINIDINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; DIARRHEA; DRUG ADSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; THRUSH; TREATMENT OUTCOME; VOMITING;

EID: 0036417340     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(02)00088-9     Document Type: Short Survey

References (43)

1. Revankar SG, Sanche SE, Dib OP, Caceres M, Patterson TF. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. AIDS 1998; 12: 2511-3.
2. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78.
3. Koks CHW, Schepens MHJ, Burger DM et al. Fluconazole in the treatment and prophylaxis of oral candidosis in HIV-infected patients. J Drug Dev 1993; 5: 235-49.
4. Fichtenbaum CJ, Koletar S, Yiannoutsos C et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000; 30: 749-56.
5. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, Kauffman CA. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1995; 38: 2495-7.
6. Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994; 8: 787-92.
7. Eichel M, Just-Nübling G, Helm EB, Stille W. Itraconazole suspension in the treatment of HIV-infected patients suffering from fluconazole-resistant oropharyngeal and oesophageal candidosis. Mycosis 1996; 39(Suppl 1): 102-6.
8. Cartledge JD, Midgley J, Youle M, Gazzard BG. Itraconazole cyclodextrin solution - Effective treatment for HIV-related candidosis unresponsive to other azole therapy. J Antimicrob Chemother 1994; 33: 1071-3.
9. De Beule K. Itraconazole: Pharmacology, clinical experience and future development. Int J Antimicrob Agents 1996; 6: 175-81.
10. Barone JA, Koh JG, Bierman RH et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37: 778-84.
11. Smith D, Van de Velde V, Woestenborghs R et al. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1992; 44: 618-9.
12. Welage LS, Carver PL, Revankar S et al. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21: 1431-8.
13. 2 blockers. J Clin Pharmacol 1997; 37: 535-40.
14. Heykants J, Van Peer A, Van de Velde V et al. The clinical pharmacokinetics of itraconazole: An overview. Mycoses 1989; 32: 67-88.
15. Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother 1992; 36: 477-80.
16. Barone JA, Moskovitz BL, Guarnieri J et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 1862-5.
17. Van de Velde V, Van Peer AP, Heykants JJP et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996; 16: 424-8.
18. Barone JA, Moskovitz BL, Guarnieri J et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998; 18: 295-301.
19. Reynes J, Bazin C, Ajana F et al. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob Agents Chemother 1997; 41: 2554-8.
20. Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999; 19: 603-11.
21. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-44.
22. Mascareñas CA, Hardin TC, Pennick GJ, Rinaldi MG, Graybill JR. Treatment of thrush with itraconazole solution: Evidence for topical effect. Clin Infect Dis 1998; 26: 1242-3.
23. National Committee for Clinical Laboratory Standards (NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard. NCCLS document M27-A. Wayne, PA: NCCLS, 1997.
24. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility testing. Clin Microbiol Rev 1993; 6: 367-81.
25. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-47.
26. Klepser ME, Wolfe EJ, Jones RN et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997; 41: 1392-5.
27. Philips P, Zemcov J, Mahmood W et al. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: Correlation of clinical response with in vitro susceptibility. AIDS 1996; 10: 1369-76.
28. Cartledge JD, Midgley J, Gazzard BG. Itraconazole cyclodextrin solution: The role of in vitro susceptibility testing in predicting succesful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. AIDS 1997; 11: 163-8.
29. Saag MS, Fessel WJ, Kaufman CA et al. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses 1999; 15: 1413-7.
30. Reynes J, Raffi F, Joly V et al. Itraconazole oral solutuion for treatment of fluconazole-resistant oral/oesophageal candidosis in HIV-infected patients: Results of a prospective multicenter study. I. Clinical assessment. J Mycol Med 1999; 9: 83-7.
31. Mallié M, Morin O, Linas M-D et al. Itraconazole oral solutuion for treatment of fluconazole-resistant oral/oesophageal candidosis in HIV-infected patients: Results of a prospective multicenter study. II. Mycological study. J Mycol Med 1999; 9: 89-96.
32. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001; 357: 1766-7.
33. Kolars JC, Lown KS, Schmiedlin-Ren P et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 247-59.
34. Miyama T, Takanaga H, Matsuo H et al. P-glycoprotein-mediated transport of itraconazole across the blood-brin barrier. Antimicrob Agents Chemother 1998; 42: 1738-44.
35. Wang E, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother 2002; 46: 160-5.
36. Malingré MM, Beijnen JH, Schellens JHM. Oral delivery of taxanes. Invest New Drugs 2001; 19: 155-62.
37. Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129-34.
38. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
39. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clinical relevance. Clin Pharmacokinet 2000; 38: 111-80.
40. Albengres E, Le Louët H, Tillement J-P. Systemic antifungal agents. Drug interactions of clinical significance. Drug Safety 1998; 18: 83-97.
41. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001; 344: 984-96.
42. Koks CHW, van Heeswijk RPG, Veldkamp AI et al. Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir. AIDS 2000; 14: 89-90.
43. Perea S, López-Ribot JL, Kirkpatrick WR et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676-84.